Search the Studies

30 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Please note that only the first 5 legal search words are being processed.

Protocol Number Title Protocol Status Min-Max Age Institute Keywords
000862-CHPilot Study of the Use of Functional Near-Infrared Spectroscopy (fNIRS) Combined with Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical ControlsParticipants currently recruited/enrolled0-125 YearsNICHDDiffuse
000860-CA Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsRecruitment has not started18-125 YearsNCI Diffuse
000633-CPhase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
000516-CPhase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous SystemParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
000326-HA Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNHLBIDiffuse
000274-CPhase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
000193-CPhase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell LymphomasClinical hold/Recruitment or enrollment suspended18-125 YearsNCI Diffuse
22-C-0003Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisParticipants currently recruited/enrolled18-39 YearsNCI Diffuse
21-C-0014Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
19-C-0116A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
19-C-0103A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)Participants currently recruited/enrolled18-125 YearsNCI Diffuse
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Diffuse
18-C-0080Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled TrialCompleted Study; data analyses ongoing5-125 YearsNCI Diffuse
17-C-0164A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNo longer recruiting/follow-up only18-125 YearsNCI Diffuse
17-C-0149Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell LymphomasNo longer recruiting/follow-up only18-125 YearsNCI Diffuse
17-C-0137Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by Invitation3-65 YearsNCI Diffuse
17-C-0127Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
17-C-0048Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell LymphomasCompleted Study; data analyses ongoing18-73 YearsNCI Diffuse
17-C-0043Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric CancerParticipants currently recruited/enrolled2-125 YearsNCI Diffuse
16-I-0078Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)Participants currently recruited/enrolled18-49 YearsNIAIDDiffuse
16-C-0097Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine GliomaCompleted Study; data analyses ongoing2-21 YearsNCI Diffuse
15-C-0078Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAsNo longer recruiting/follow-up only18-65 YearsNCI Diffuse
14-C-0157Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
10-C-0052Phase II Study of Dose-Adjusted EPOCH +/-Rituximab in Adults with Untreated Burkitt Lymphoma, c-MYC+ Diffuse Large B-Cell Lymphoma and Plasmablastic LymphomaCompleted Study; data analyses ongoing18-125 YearsNCI Diffuse
10-C-0011Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Diffuse
06-C-0219An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System TumorsCompleted Study; data analyses ongoing0-21 YearsNCI Diffuse
05-C-0252Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Diffuse
01-C-0030Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated LymphomasNo longer recruiting/follow-up only18-125 YearsNCI Diffuse
93-C-0133Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's LymphomaNo longer recruiting/follow-up only12-125 YearsNCI Diffuse